不同方案治疗重度AECOPD细菌感染的成本——效果分析

Cost-effectiveness analysis of different regimens in treatment of severe AECOPD bacterial infections

目的比较两种抗菌药物治疗重度慢性阻塞性肺疾病急性加重期(AECOPD)细菌感染的成本—效果,为临床选用抗菌药物提供参考。方法通过HIS系统,选取2017年3月-2018年6月德阳市第二人民医院呼吸内科老年病区收治的重度AECOPD患者126例,按照治疗方案不同分为A组66例和B组60例。A组给予头孢哌酮钠/他唑巴坦钠治疗,B组采用哌拉西林钠/他唑巴坦钠治疗。观察2组患者治疗后临床疗效、不良反应发生情况,并进行成本—效果分析。结果A组总有效率为80.30%,B组总有效率为78.33%,2组总有效率比较无统计学意义(P>0.05)。2组不良反应发生率比较无统计学意义(P>0.05)。A组的成本—效果比低于B组。结论与哌拉西林钠/他唑巴坦钠相比,头孢哌酮钠/他唑巴坦钠治疗重度AECOPD细菌感染更经济。

Objective To compare the cost-effectiveness of two antibacterial drugs on bacterial infection of acute exacerbation of severe chronic obstructive pulmonary disease(AECOPD),and provide a reference for clinical use of antibacterial drugs.Methods Through the HIS system,126 patients with severe AECOPD who were treated in the geriatric ward of the Department of Respiratory Medicine of The Second People’s Hospital of Deyang City from March 2017 to June 2018 were selected.According to different treatment schemes,they were divided into 66 cases in group A and 60 cases in group B.Group A was treated with cefoperazone sodium/tazobactam sodium,and group B was treated with piperacillin sodium/tazobactam sodium.The clinical efficacy and adverse reactions of the two groups were observed and the cost-effectiveness analysis was performed.Results The total effective rate of group A was 80.30%,and the total effective rate of group B was 78.33%,the total effective rate of the two groups was not statistically significant(P>0.05).The incidence of adverse reactions in the two groups was not statistically significant(P>0.05).The cost-effectiveness ratio of group A was lower than that of group B.Conclusion Compared with piperacillin sodium/tazobactam sodium,cefoperazone sodium/tazobactam sodium is more economical in treating severe AECOPD bacterial infections.